| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rovazolac targets the liver X receptor (LXR), a nuclear receptor that regulates cholesterol metabolism and inflammatory responses. As an LXR modulator, it modulates the receptor's activity to exert anti-inflammatory effects. The compound is an LXR modulator extracted from patent WO2013130892A1.
|
|---|---|
| ln Vitro |
One potential anti-inflammatory medication is rovazolac [1].
In biochemical assays, rovazolac acts as an LXR modulator. The compound is an anti-inflammatory drug candidate. Detailed IC₅₀ values and binding affinities for LXR would be characterized in cell-free receptor binding and transactivation assays. |
| ln Vivo |
In cellular models, rovazolac modulates LXR-mediated gene expression, leading to anti-inflammatory effects. Cells treated with the compound show changes in the expression of LXR target genes involved in lipid metabolism and inflammation. Detailed cellular activity data are described in the primary literature.
|
| Enzyme Assay |
The in vitro LXR modulation assay involves incubating cells expressing LXR with a reporter gene construct and varying concentrations of rovazolac. LXR activation is assessed by measuring reporter gene activity. Binding affinity is determined using radioligand binding or fluorescence polarization assays with purified LXR protein.
|
| Cell Assay |
Cells are cultured and treated with rovazolac at concentrations ranging from 1 nM to 100 µM. LXR target gene expression is measured by qRT-PCR. Anti-inflammatory effects are assessed by measuring cytokine production in stimulated immune cells. Cell viability is monitored to assess compound toxicity.
|
| Animal Protocol |
In vivo studies have been conducted in clinical trial NCT03175354 for patients with moderate atopic dermatitis. Rovazolac is being studied for the topical treatment of cutaneous inflammatory disorders. Endpoints include assessment of skin inflammation, lesion improvement, and safety.
|
| ADME/Pharmacokinetics |
Rovazolac (C₂₁H₁₉F₃N₂O₄S, MW 452.45, CAS 1454288-88-0) is a small molecule compound. It is soluble in ethanol (~10 mg/mL). The compound is typically stored as a powder at -20°C for up to 3 years. In vivo formulations include 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology data for rovazolac are being evaluated as part of its clinical development program. The compound is for research use only and is not yet approved for clinical use. Clinical trial safety data are being collected in ongoing studies (NCT03175354).
|
| References | |
| Additional Infomation |
Rovazolac is being studied in the clinical trial NCT03175354 (a study of patients with moderate atopic dermatitis).
Rovazolac (INN, also known as ALX-101) is an LXR modulator being investigated for the topical treatment of moderate atopic dermatitis. The compound is an anti-inflammatory drug candidate. It is in clinical development and is intended for research use only. |
| Molecular Formula |
C21H19F3N2O4S
|
|---|---|
| Molecular Weight |
452.446774721146
|
| Exact Mass |
452.101
|
| CAS # |
1454288-88-0
|
| PubChem CID |
89792952
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
625.8±55.0 °C at 760 mmHg
|
| Flash Point |
332.3±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.570
|
| LogP |
4.02
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
717
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)CN1C(=CC(=N1)C(F)(F)F)C2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C
|
| InChi Key |
ZUMNJDGBYXHASJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3
|
| Chemical Name |
ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~10 mg/mL (~22.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.53 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.53 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2102 mL | 11.0509 mL | 22.1019 mL | |
| 5 mM | 0.4420 mL | 2.2102 mL | 4.4204 mL | |
| 10 mM | 0.2210 mL | 1.1051 mL | 2.2102 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03859986
Conditions:Atopic Dermatitis EczemaLink: https://clinicaltrials.gov/ct2/show/NCT00636285
Conditions:Staphylococcal SepsisProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
